0001104659-24-092491.txt : 20240823 0001104659-24-092491.hdr.sgml : 20240823 20240823170057 ACCESSION NUMBER: 0001104659-24-092491 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240821 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240823 DATE AS OF CHANGE: 20240823 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Entero Therapeutics, Inc. CENTRAL INDEX KEY: 0001604191 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464993860 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37853 FILM NUMBER: 241237082 BUSINESS ADDRESS: STREET 1: 777 YAMATO ROAD STREET 2: SUITE 502 CITY: BOCA RATON STATE: FL ZIP: 33431 BUSINESS PHONE: 561-589-7020 MAIL ADDRESS: STREET 1: 777 YAMATO ROAD STREET 2: SUITE 502 CITY: BOCA RATON STATE: FL ZIP: 33431 FORMER COMPANY: FORMER CONFORMED NAME: First Wave BioPharma, Inc. DATE OF NAME CHANGE: 20210921 FORMER COMPANY: FORMER CONFORMED NAME: AzurRx BioPharma, Inc. DATE OF NAME CHANGE: 20141103 FORMER COMPANY: FORMER CONFORMED NAME: BioPharma d'Azur, Inc. DATE OF NAME CHANGE: 20140331 8-K 1 tm2422567d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 21, 2024

	Entero Therapeutics, Inc.
	(Exact name of registrant as specified in its charter)

Delaware		001-37853		46-4993860
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

777 Yamato Road, Suite 502

Boca Raton, Florida

33431

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (561) 589-7020

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ENTO		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously reported in a Form 12b-25 Notification of Late Filing filed by Entero Therapeutics, Inc. (the “Company”), on August 15, 2024, the Company is delayed in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the “Form 10-Q”) with the U.S. Securities and Exchange Commission (the “SEC”) because it is in the process of engaging a new independent registered public accounting firm.

On August 21, 2024, the Company received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that, because the Company has not timely filed its Form 10-Q, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires companies with securities listed on Nasdaq to timely file all required periodic reports with the SEC. The Company has sixty (60) days, or until October 21, 2024, to submit a plan to regain compliance with the Rule to Nasdaq. If Nasdaq approves such a plan, it has the discretion to grant the Company an extension of up to 180 calendar days, or until February 17, 2025, to regain compliance with the Rule. The Notice has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market. The Company is in the process of engaging a new independent registered public accounting firm and intends to take the necessary steps to regain compliance with the Rule as soon as practicable.

On August 23, 2024, the Company issued a press release announcing its receipt of the Notice (the “Press Release”). The Press Release is attached hereto as Exhibit 99.1 and is being filed herewith.

Item 9.01

Financial Statements and Exhibits.

99.1		Press Release, dated August 23, 2024
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Entero Therapeutics, Inc.

August 23, 2024	By:	/s/ James Sapirstein
	Name:	James Sapirstein
	Title:	Chief Executive Officer

EX-99.1 2 tm2422567d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

BOCA RATON, Fla., August 23, 2024 (GLOBE NEWSWIRE) – Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) advising that, because the Company failed to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 (the “Form 10-Q”), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”). Nasdaq has informed the Company that it has until October 21, 2024, to submit a plan to regain compliance with the Rule. If Nasdaq approves the Company’s plan, it has the discretion to grant the Company an extension of up to 180 calendar days from the due date of the Form 10-Q (or until February 17, 2025) to regain compliance.

As the Company previously reported, Forvis Mazars, LLP resigned as the Company’s independent registered public accountants on August 9, 2024. The Company is currently in the process of engaging a new independent registered public accounting firm and will use its best efforts to file the Form 10-Q prior to October 21, 2024. If the Company does not file the Form 10-Q in advance of the sixty-day deadline, it intends to timely file a plan to regain compliance with Nasdaq. There can be no assurance, however, that the Company will be able to regain compliance with the listing requirements discussed above or otherwise satisfy the other Nasdaq listing criteria. This notification has no immediate effect on the listing of the Company’s securities on Nasdaq.

About Entero Therapeutics, Inc.

Entero Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company currently has a therapeutic development pipeline with multiple late-stage clinical programs built around three proprietary technologies: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist being developed for gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. Entero Therapeutics is headquartered in Boca Raton, Florida. For more information visit www.enterothera.com.

Forward-Looking Statements

This press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including the Company’s current and future capital requirements and its ability to raise additional funds to satisfy its capital needs; whether there are delays in the engagement of a new independent registered public accounting firm; whether there are any further delays in the preparation and filing of the Company’s Form 10-Q; whether any financing or licensing transaction may be obtained, completed in an untimely manner, or not at all; whether the Company will be able to realize the expected benefits of its acquisition of ImmunogenX; the Company’s ability to integrate the assets and contemplated commercial operations acquired from ImmunogenX into the Company’s business; whether the Company will be able to effectively and timely service its debt; whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; whether the Company will be able to maintain compliance with Nasdaq’s continued listing criteria and the effect of a delisting from Nasdaq on the market for the Company’s securities; whether the Company will be able to satisfy the terms of any plan of compliance it submits to Nasdaq; whether Nasdaq will accept any plan of compliance the Company submits, or provide any other accommodations to the Company; the size of the potential markets for the Company’s drug candidates and its ability to service those markets; and the effects of the First Wave Bio, Inc. acquisition, the related settlement and their effect on the Company’s business, operating results and financial prospects. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company’s financial results are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, under the heading “Risk Factors,” as well as the Company’s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

For more information:

Entero Therapeutics, Inc.

777 Yamato Road, Suite 502

Boca Raton, FL 33431

Phone: (561) 589-7020

info@enterothera.com

Media contact:

Russo Partners

David Schull or Liz Phillips

(347) 956-7697

david.schull@russopartnersllc.com

elizabeth.phillips@russopartnersllc.com

EX-101.SCH 3 fwbi-20240821.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 fwbi-20240821_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 fwbi-20240821_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2422567d1_ex99-1img001.jpg GRAPHIC begin 644 tm2422567d1_ex99-1img001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	Aug. 21, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Aug. 21, 2024
Entity File Number	001-37853
Entity Registrant Name	Entero Therapeutics, Inc.
Entity Central Index Key	0001604191
Entity Tax Identification Number	46-4993860
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	777 Yamato Road
Entity Address, Address Line Two	Suite 502
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33431
City Area Code	561
Local Phone Number	589-7020
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	ENTO
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://firstwavebio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports fwbi-20240821.xsd fwbi-20240821_lab.xml fwbi-20240821_pre.xml tm2422567d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2422567d1_8k.htm": { "nsprefix": "FWBI", "nsuri": "http://firstwavebio.com/20240821", "dts": { "schema": { "local": [ "fwbi-20240821.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "fwbi-20240821_lab.xml" ] }, "presentationLink": { "local": [ "fwbi-20240821_pre.xml" ] }, "inline": { "local": [ "tm2422567d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://firstwavebio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-08-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2422567d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-08-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2422567d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://firstwavebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-092491-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-092491-xbrl.zip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end XML 17 tm2422567d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001604191 2024-08-21 2024-08-21 iso4217:USD shares iso4217:USD shares false 0001604191 8-K 2024-08-21 Entero Therapeutics, Inc. DE 001-37853 46-4993860 777 Yamato Road Suite 502 Boca Raton FL 33431 561 589-7020 false false false false Common Stock, par value $0.0001 per share ENTO NASDAQ false